$CHRS News

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Coherus to Participate in Upcoming Investor Conferences

Coherus Oncology Files Prospectus For Offering $50M Common Shares

Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets

Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript

Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology, Inc. Q2 2026 Earnings Call Summary

Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ...

Coherus Oncology Q2 Earnings Call Highlights

Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Coherus BioSciences Q2 Adj. EPS $(0.19) Beats $(0.20) Estimate, Sales $14.307M Miss $14.400M Estimate

Coherus Oncology: The Catalyst Rich Period Is Here

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026